June 14, 2013
A Pennsylvania federal judge on Friday approved a $150 million settlement, including $50 million in attorneys' fees, ending a direct purchaser antitrust class action accusing GlaxoSmithKline of filing sham petitions with federal authorities to delay generic alternatives to Flonase nasal spray.
November 01, 2012
A Pennsylvania federal judge struck a blow to GlaxoSmithKline PLC on Thursday, ruling that plaintiffs in a class action accusing it of illegally blocking development of a generic Flonase could tap former U.S. Food and Drug Administration chief David Kessler as an expert witness.
June 02, 2011
GlaxoSmithKline PLC on Thursday lost a bid for summary judgment in three antitrust cases pending in Pennsylvania that allege the company delayed sales of a generic version of Flonase by filing baseless petitions with the U.S. Food and Drug Administration.